Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

about

Regulatory T Cells and Ocular Graft Versus Host Disease: A Novel Treatment Approach

P2860

Q58597201-FC36FA97-0A11-4D20-B301-CA2B3E315BF1

P2860

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

Item

http://www.wikidata.org/entity/Q54937398

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

@en

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

@nl

type

Item

label

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

@en

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

@nl

prefLabel

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

@en

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

@nl

P1476

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

@en

P2093

Jianhua Yu

http://www.w3.org/2001/XMLSchema#string

Lingling Zhang

http://www.w3.org/2001/XMLSchema#string

Wei Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Tolerogenic dendritic cells and negative vaccination in transplantation: from rodents to clinical trials

Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy

Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses

Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients.

A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity

Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects

Conformal Nanoencapsulation of Allogeneic T Cells Mitigates Graft-versus-Host Disease and Retains Graft-versus-Leukemia Activity.

A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.

P304

1087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2018.01087

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29868032

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5964137

http://www.w3.org/2001/XMLSchema#string

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

about

P2860

P2860

Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932